E-ISSN 2231-170X | ISSN 2231-1696
 

Original Article 


Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)

Emmy Palinggi, Muhammad Asykar Palinrungi, Achmad M. Palinrungi, Arifin Seweng, Khoirul Kholis, Syakri Syahrir, Syarif Syarif, Muhammad Faruk.

Cited By: 2

Abstract
Lower urinary tract symptoms (LUTS) and ureteral-stent-related symp-toms (uSRS) are similar to those of lower urinary tract symptoms caused by benign prostatic hypertrophy (BPH), and complaints about urgency and frequency of urination are the same as in patients with overactive bladder syndrome (OAB). β₃-adrenoceptor agonist (Mirabegron) and anti-muscarinic (Solifenacin) therapies used for LUTS and OAB therapy can also be used to reduce SRS complaints. This study aimed to determine the effectiveness of using Solifenacin as a treatment for uSRS as compared to Mirabegron. This study used a double-blinded experimental design. Samples were taken randomly (consecutive random sampling) from fifty patients with uSRS. Data was collected using the Ureteral Symptoms Score Questionnaire (USSQ) as a measuring instrument. Data was analyzed using the mean, t-Test, and Chi-square tests. P values of <0.05 were considered to be statistically significant. Treatment by administering 5 mg/day of Solifenacin was compared with that of 50 mg/day of Mirabegron demonstrates a fairly good result of lowering the LUTS score complaint where the average score values measured were according to urinary symptoms (5.64 vs. 6.08, p = 0.53), pain (4.48 vs. 4.52, p = 0.96), general condition (3.6 vs. 3.2, p = 0.96), work activity (2.08 vs. 2.04, p = 0.044), sexual activity (1.00 vs. 1.32, p = 0.42), and other complaints (2.48 vs. 4.00, p= 0.001). The average rate reduction of USSQ urinary symptoms, pain, general circumstances and work activity was greater in Solifenacin group. These results show insignificant differences in symptom reduction, except in the variables of work activity (AK) and other complaints (TOS).

Key words: Mirabegron, Solifenacin, Stent-related symptoms, USSQ


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Emmy Palinggi
Articles by Muhammad Asykar Palinrungi
Articles by Achmad M. Palinrungi
Articles by Arifin Seweng
Articles by Khoirul Kholis
Articles by Syakri Syahrir
Articles by Syarif Syarif
Articles by Muhammad Faruk
on Google
on Google Scholar


This Article Cited By the following articles

Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis
European Urology Focus 2021; (): .

1
 
Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis
European Urology Focus 2022; 8(4): 1031.

2
 
How to Cite this Article
Pubmed Style

Palinggi E, Palinrungi MA, Palinrungi AM, Seweng A, Kholis K, Syahrir S, Syarif S, Faruk M. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). J Med Allied Sci. 2020; 10(2): 115-120. doi:10.5455/jmas.113358


Web Style

Palinggi E, Palinrungi MA, Palinrungi AM, Seweng A, Kholis K, Syahrir S, Syarif S, Faruk M. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). https://jmas.in/?mno=113358 [Access: December 05, 2023]. doi:10.5455/jmas.113358


AMA (American Medical Association) Style

Palinggi E, Palinrungi MA, Palinrungi AM, Seweng A, Kholis K, Syahrir S, Syarif S, Faruk M. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). J Med Allied Sci. 2020; 10(2): 115-120. doi:10.5455/jmas.113358



Vancouver/ICMJE Style

Palinggi E, Palinrungi MA, Palinrungi AM, Seweng A, Kholis K, Syahrir S, Syarif S, Faruk M. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). J Med Allied Sci. (2020), [cited December 05, 2023]; 10(2): 115-120. doi:10.5455/jmas.113358



Harvard Style

Palinggi, E., Palinrungi, . M. A., Palinrungi, . A. M., Seweng, . A., Kholis, . K., Syahrir, . S., Syarif, . S. & Faruk, . M. (2020) Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). J Med Allied Sci, 10 (2), 115-120. doi:10.5455/jmas.113358



Turabian Style

Palinggi, Emmy, Muhammad Asykar Palinrungi, Achmad M. Palinrungi, Arifin Seweng, Khoirul Kholis, Syakri Syahrir, Syarif Syarif, and Muhammad Faruk. 2020. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). Journal of Medical and Allied Sciences, 10 (2), 115-120. doi:10.5455/jmas.113358



Chicago Style

Palinggi, Emmy, Muhammad Asykar Palinrungi, Achmad M. Palinrungi, Arifin Seweng, Khoirul Kholis, Syakri Syahrir, Syarif Syarif, and Muhammad Faruk. "Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)." Journal of Medical and Allied Sciences 10 (2020), 115-120. doi:10.5455/jmas.113358



MLA (The Modern Language Association) Style

Palinggi, Emmy, Muhammad Asykar Palinrungi, Achmad M. Palinrungi, Arifin Seweng, Khoirul Kholis, Syakri Syahrir, Syarif Syarif, and Muhammad Faruk. "Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)." Journal of Medical and Allied Sciences 10.2 (2020), 115-120. Print. doi:10.5455/jmas.113358



APA (American Psychological Association) Style

Palinggi, E., Palinrungi, . M. A., Palinrungi, . A. M., Seweng, . A., Kholis, . K., Syahrir, . S., Syarif, . S. & Faruk, . M. (2020) Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). Journal of Medical and Allied Sciences, 10 (2), 115-120. doi:10.5455/jmas.113358